Key Highlights
● McKesson rose 1.40% to close at $994.58 on October 30, 2026.
● Morgan Stanley raised its target to $1,207 from $977.
● It kept an Overweight rating.
● Fiscal second-quarter results are due on November 4.
Why did McKesson (NYSE:MCK) gain on one of the worst days for the market since June? Mostly an analyst call plus a defensive rotation. The drug distributor, which trades on the New York Stock Exchange under the ticker MCK and is a member of the S&P 500, closed Friday, October 30, 2026 at $994.58, up $13.70 or 1.40%, according to market data. The S&P 500 fell 1.82% that day, according to market data. The company-specific catalyst was a price-target increase from Morgan Stanley (NYSE:MS). An analyst raised the target to $1,207 from $977 and kept an Overweight rating on Friday. The reasoning was not given. The new target implies about 21% upside from Friday's close.
A two-day rebound into earnings
Friday's gain followed a 2.12% rise on October 29, according to market data price history. Together the two sessions recovered most of the ground lost earlier in the week, when the shares fell 2.60% on October 27 and 0.67% on October 28. The stock remains a little below its 52-week high of $1,030.27, and well above its 52-week low of $723.68.
Morgan Stanley was not alone in raising its view. Market data lists recent target increases from UBS (NYSE:UBS), to $1,200 from $1,080 with a Buy rating, and Mizuho (NYSE:MFG), to $1,020 from $905 with a Neutral rating. Health care also offered shelter on Friday. As technology shares sank after results from Intel (NASDAQ:INTC) and Amazon (NASDAQ:AMZN), market reports said Regeneron (NASDAQ:REGN) rose more than 11% on earnings, and Stocktitan noted that drugmakers AstraZeneca (NASDAQ:AZN) and Sanofi (NASDAQ:SNY) rose before the open. Drug distribution, with steady volumes and little exposure to the AI trade, fit that defensive profile.
What McKesson does
McKesson is one of the largest pharmaceutical distributors in the United States. It buys drugs from manufacturers and delivers them to pharmacies, hospitals and clinics. It also runs an oncology and specialty network, a prescription technology Business that helps patients access medicines, and a medical-surgical supplies distribution unit. In its fiscal 2027 first quarter, the North American Pharmaceutical segment produced $86.8 billion of revenue, Oncology and Multispecialty $14.2 billion, Prescription Technology Solutions $1.6 billion and Medical-Surgical Solutions $2.8 billion, according to the company's release.
That Volume explains McKesson's place on A list of US companies with the highest Revenue per employee. Market data lists trailing twelve-month revenue of $410.98 billion and about 43,000 employees, or roughly $9.6 million of revenue per employee. Distribution is a thin-margin, high-throughput business. The full cost of the drugs passes through McKesson's revenue line, inflating sales relative to headcount.
Recent financials
McKesson reported fiscal first-quarter results on August 5. Revenue rose 8% to $105.4 billion, and adjusted Earnings per share rose 20% to $9.93, according to the company's release. GAAP EPS fell to $5.15 from $6.25, mainly because of a $293 million Redemption value adjustment tied to non-controlling interests in Medical-Surgical Solutions. Adjusted operating profit rose 19% in North American Pharmaceutical and 41% in Oncology and Multispecialty but fell 20% in Medical-Surgical Solutions.
The company raised full-year fiscal 2027 adjusted EPS guidance to $44.20 to $45.00, implying 13% to 15% growth, and market data noted that McKesson reaffirmed that range around October 1. It repurchased $2.5 billion of stock in the quarter, including a $2.25 billion accelerated buyback. CEO Brian Tyler said McKesson "delivered a strong start to fiscal 2027, underscored by momentum across the enterprise."
Deals and contracts
McKesson has been busy. Market data lists an agreement in principle to extend its pharmaceutical distribution agreement with CVS Health (NYSE:CVS), which BofA called a "clearing event," and a $741.5 million Defense Logistics Agency contract award. The company agreed to buy Precision Medicine Group for about $2.25 billion in August. In October, McKesson and Clayton Dubilier & Rice agreed to acquire Option Care Health at an Enterprise value of about $5.8 billion. According to market data, McKesson would invest about $1.4 billion for a roughly 49% stake, with closing expected in the first half of calendar 2027, subject to Shareholder and regulatory approvals.
Valuation
Market data shows a market Capitalization of about $116 billion, a trailing P/E of 26.5 and a forward P/E of 21.4. On the midpoint of company guidance, Friday's close is roughly 22 times fiscal 2027 adjusted EPS. The quarterly Dividend is $0.94 per share, a Yield of about 0.38%, with the next ex-dividend date on December 1. The consensus rating is Buy from 16 analysts, with an average target of $1,026.07, about 3% above the close. Morgan Stanley's new target sits well above that average.
Sector context
Drug distributors have benefited from steady prescription volumes, growth in specialty and oncology drugs, and rising use of costly branded therapies. Morgan Stanley has called this a "golden era" for drug distribution in past research, according to an April 2025 report on market data. On a day when investors fled high-growth technology, McKesson's predictable cash flows looked appealing.
Risks
Valuation is one risk. After a rally of more than 35% from its 52-week low, the stock sits only about 3% below the consensus target, leaving less room for disappointment. Customer concentration is another; the CVS agreement is only an agreement in principle until finalized. Medical-Surgical Solutions remains weak. Acquisitions such as Option Care Health and Precision Medicine Group add execution and regulatory risk. Market data also listed an August 31 report in which hackers claimed to have stolen millions of patient records in a cyberattack on McKesson. Drug pricing policy remains an industry-wide uncertainty.
What to watch next
The next big test comes quickly. McKesson will report fiscal second-quarter 2027 results on November 4, 2026, according to market data. Investors will look for whether the company raises its $44.20 to $45.00 adjusted EPS range again, trends in oncology and specialty, a turnaround in Medical-Surgical Solutions, and updates on the CVS contract and Option Care Health deal. The pace of Buybacks will also be watched. If results support the bullish targets from Morgan Stanley and UBS, the stock could test its 52-week high. A miss after this run could prove costly.






Please wait processing your request...